Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Bought by Rock Springs Capital Management LP

Rock Springs Capital Management LP raised its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 8.6% in the 1st quarter, Holdings Channel reports. The fund owned 351,828 shares of the company’s stock after purchasing an additional 27,813 shares during the period. Rock Springs Capital Management LP’s holdings in Centessa Pharmaceuticals were worth $13,975,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Virtus Investment Advisers LLC boosted its stake in shares of Centessa Pharmaceuticals by 6.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock valued at $251,000 after purchasing an additional 583 shares during the period. Coastal Bridge Advisors LLC grew its holdings in Centessa Pharmaceuticals by 7.1% during the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock valued at $351,000 after purchasing an additional 931 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Centessa Pharmaceuticals by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the 4th quarter worth $25,000. Finally, Wells Fargo & Company MN lifted its holdings in Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after buying an additional 1,008 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of analyst reports. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Wells Fargo & Company lowered Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target on the stock. in a research note on Monday, April 13th. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $40.50 on Tuesday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The company has a fifty day simple moving average of $40.16 and a 200 day simple moving average of $33.89. The firm has a market cap of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $12.74 and a 12-month high of $40.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, equities research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.